Hematologic response achieved with various chemotherapy combinations on an ITT basis. The response rates for thalidomide-based combinations were: CR/VGPR 30 (31%), PR 29 (30%); for melphalan-dexamethasone: CR/VGPR 11 (18%), PR 22 (35%); for bortezomib-based regimens: CR/VGPR 16 (61%), PR 2 (8%); for other alkylators: CR/VGPR 3(43%), PR 0 (0%); and for regimens for lymphoplasmacytic lymphoma (LPL): CR/VGPR 3 (14%), PR 8 (38%).